natgillin/translations-raw huggingface dataset:
Plavix is supplied in cardboard cartons containing: 7, 14, 28, 30, 84, 90 and 100 tablets in PVC/PVDC/Aluminium blisters or in all aluminium blisters 
Plavix je dostupan u kartonskim kutijama koje sadrže: 7, 14, 28, 30, 84, 90 i 100 tableta u PVC/PVDC/aluminij blisterima ili u aluminijskim blisterima
Hypromellose (E464) Lactose monohydrate Triacetin (E1518) Titanium dioxide (E171) Red iron oxide (E172) 
Ovojnica: hipromeloza (E464) laktoza hidrat triacetin (E1518) titanijev dioksid (E171) željezov oksid, crveni (E172)
If you experience prolonged bleeding when taking Plavix 
Ako pri uzimanju Plavixa imate produljeno krvarenje
Polishing agent: Carnauba wax 
Sredstvo za poliranje: karnauba vosak
• Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section 
• Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 2 ili dijelu 6.1.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/ 
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu/
It also contains: hydrogenated castor oil and lactose. 
POPIS POMOĆNIH TVARI Također sadrži: hidrogenirano ricinusovo ulje i laktozu.
You have been prescribed Plavix to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack). 
Plavix Vam je propisan za sprječavanje stvaranja krvnih ugrušaka i smanjivanje opasnosti od ovih ozbiljnih događaja jer: - imate otvrdnuće arterija (koje se još zove ateroskleroza) te - ste već imali srčani udar, moždani udar ili imate stanje koje se zove bolest perifernih arterija, ili - ste imali teški oblik boli u prsištu, poznat pod nazivom “nestabilna angina” ili “infarkt miokarda” (srčani udar).
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the coadministration of phenobarbital or oestrogen. 
Nadalje, na farmakodinamičku aktivnost klopidogrela nije značajno utjecala istodobna primjena fenobarbitala ili estrogena.
These occurred at doses representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic metabolising enzymes. 
One su se javljale pri dozama koje su odgovarale barem 25 puta većoj izloženosti od one u bolesnika koji su primali kliničku dozu od 75 mg klopidogrela na dan i bile su posljedice učinka na jetrene metaboličke enzime.
• Adult patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). 
• odraslih bolesnika koji boluju od akutnog koronarnog sindroma: - Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda), uključujući bolesnike koji se podvrgavaju ugradnji stenta nakon perkutane koronarne intervencije, u kombinaciji s acetilsalicilatnom kiselinom (ASK).
• If you cut or injure yourself, it may take longer than usual for bleeding to stop. 
• Ako se porežete ili ozlijedite, možda će biti potrebno više vremena da se krvarenje zaustavi.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER / 30, 50x1, 90 or 100 tablets 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP BLISTER / 30, 50x1, 90 ili 100 tableta
Overall, 645 of 646 patients with ST-elevation-MI (STEMI) or non-ST-elevation-MI (NSTEMI) or unstable angina were analyzed (de-escalated DAPT (n=322); unchanged DAPT (n=323)). 
Sveukupno je ispitano 645 od 646 bolesnika s infarktom miokarda sa ST elevacijom (STEMI), infarktom miokarda bez ST elevacije (NSTEMI) i nestabilnom anginom (smanjeni DAPT (n=322); nepromijenjen DAPT (n=323)).
If Plavix is supplied in all aluminium blisters, it does not require any special storage conditions. 
Ako je Plavix opremljen u aluminijske blistere, lijek ne zahtijeva posebne uvjete čuvanja.
If a dose is missed: - Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
Propuštena doza: - Ako je prošlo manje od 12 sati nakon uobičajenog termina uzimanja lijeka: bolesnik treba odmah uzeti dozu, a sljedeću dozu treba uzeti prema uobičajenom rasporedu.
28 film-coated tablets 30 film-coated tablets 50x1 film-coated tablets 84 film-coated tablets 90 film-coated tablets 100 film-coated tablets 14 film-coated tablets 7 film-coated tablets 
28 filmom obloženih tableta 30 filmom obloženih tableta 50x1 filmom obloženih tableta 84 filmom obložene tablete 90 filmom obloženih tableta 100 filmom obloženih tableta 14 filmom obloženih tableta 7 filmom obloženih tableta
• Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. 
• odraslih bolesnika koji su pretrpjeli infarkt miokarda (u rasponu od nekoliko do najviše 35 dana), ishemijski moždani udar (u rasponu od 7 dana do najviše 6 mjeseci) ili imaju utvrđenu bolest perifernih arterija.
TOPIC (Timing Of Platelet Inhibition after acute Coronary syndrome) This randomized, open-label trial included ACS patients requiring percutaneous coronary intervention (PCI). 
Timing of Platelet Inhibition after Acute Coronary Syndrome) Ovo randomizirano, otvoreno ispitivanje uključivalo je bolesnike s akutnim koronarnim sindromom u kojih je bila potrebna perkutana koronarna intervencija (PCI).
Plavix is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Plavix uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
The most common side effect reported with Plavix is bleeding. 
Najčešća nuspojava Plavixa jest krvarenje.
Calendar days Mon 
Kalendarski dani Pon
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8) 
Incidencija klinički značajnog krvarenja bila je slična onoj zamijećenoj pri istodobnoj uporabi trombolitika i heparina s ASK (vidjeti dio 4.8.).
Excipients with known effect: Each film-coated tablet contains 12 mg of lactose and 13.2 mg of hydrogenated castor oil. 
Pomoćne tvari s poznatim učinkom: Jedna filmom obložena tableta sadrži 12 mg laktoze i 13,2 mg hidrogeniranog ricinusovog ulja.
If you stop taking Plavix Do not stop the treatment unless your doctor tells you so. 
Ne prekidajte liječenje osim ako Vam to ne savjetuje liječnik.
Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)* 
Poremećaji imunološkog sustava serumska bolest, anafilaktoidne reakcije, križno reaktivna preosjetljivost na lijekove iz skupine tienopiridinima (kao što su tiklopidin, prasugrel) (vidjeti dio 4.4)*, autoimuni inzulinski sindrom koji može dovesti do teške hipoglikemije, osobito u bolesnika s podtipom HLA DRA4 (češći u japanskoj populaciji)*
• Paediatric population Clopidogrel should not be used in children because of efficacy concerns (see section 5.1). 
• Pedijatrijska populacija Klopidogrel se ne primjenjuje u djece zbog nedovoljnih podataka o djelotvornosti (vidjeti dio
− Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.4). 
Oralni antikoagulansi: istodobna primjena klopidogrela i oralnih antikoagulansa se ne preporučuje, jer se može povećati intenzitet krvarenja (vidjeti dio 4.4.).
This may cause stomach upset or diarrhoea. 
To može uzrokovati želučane tegobe i proljev.
A significantly reduced platelet inhibition has been shown in HIV patients treated with ritonavir-or cobicistat-boosted ART. 
Značajno smanjena inhibicija trombocita zabilježena je u nekih bolesnika s HIV infekcijom liječenih ritonavirom-ili-kobicistatom-pojačanom ART.
De-escalation of P2Y12 Inhibitor Agents in Acute Coronary Syndrome Switching from a more potent P2Y12 receptor inhibitor to clopidogrel in association with aspirin after acute phase in Acute Coronary Syndrome (ACS) has been evaluated in two randomized investigatorsponsored studies (ISS) - TOPIC and TROPICAL-ACS - with clinical outcome data. 
Prelazak s potentnijeg inhibitora P2Y12 receptora na klopidogrel u kombinaciji s acetilsalicilatnom kiselinom nakon akutne faze akutnog koronarnog sindroma (ACS) ispitan je u dva randomizirana ispitivanja sponzorirana od strane ispitivača (engl. investigator-sponsored studies, ISS) TOPIC i TROPICAL-ACS, s podacima o kliničkim ishodima.
50x1 tablets in PVC/PVDC/Aluminium blisters or in all aluminium perforated unit-dose blisters. 
50x1 tableta u PVC/PVDC/aluminij blisterima ili u perforiranim aluminijskim blisterima s jediničnim dozama.
Excipients with known effect: Each film-coated tablet contains 3 mg of lactose and 3.3 mg of hydrogenated castor oil. 
Pomoćne tvari s poznatim učinkom: Jedna filmom obložena tableta sadrži 3 mg laktoze i 3,3 mg hidrogeniranog ricinusovog ulja.
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking Plavix 75 mg/day. 
S dozom od 0,2 mg/kg postignut je prosječni postotak inhibicije od 49,3% (5 µM ADP-om inducirane agregacije trombocita), što je usporedivo s postotkom u odraslih koji uzimaju Plavix u dozi od 75 mg/dnevno.
It is preferable not to take this product during pregnancy. 
Ne preporučuje se uzimanje Plavixa za vrijeme trudnoće.
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4). 
• Oštećenje funkcije bubrega Terapijsko iskustvo u bolesnika s narušenom funkcijom bubrega je ograničeno (vidjeti dio 4.4.).
4x1 film-coated tablets 30x1 film-coated tablets 100x1 film-coated tablets 10x1 film-coated tablets 
4x1 filmom obložene tablete 30x1 filmom obloženih tableta 100x1 filmom obloženih tableta 10x1 filmom obloženih tableta
In all aluminium blisters, this medicinal product does not require any special storage conditions. 
Lijek u aluminijskim blisterima ne zahtijeva posebne uvjete čuvanja.
How to store Plavix 
Kako čuvati Plavix
sanofi-aventis groupe 
Nositelj odobrenja: sanofi-aventis groupe
Sanofi Winthrop Industrie 1, rue de la Vierge Ambarès & Lagrave F-33565 Carbon Blanc cedex France 
Sanofi Winthrop Industrie 1, rue de la Vierge Ambarès & Lagrave F-33565 Carbon Blanc cedex Francuska
Store below 30°C (for PVC/PVDC/aluminium blisters) Or No special storage conditions (for all aluminium blisters) 
POSEBNE MJERE ČUVANJA Čuvati na temperaturi ispod 30°C (za PVC/PVDC/Al blistere) Ili Nema posebnih uvjeta čuvanja (za aluminijske blistere)
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day. 
Nakon ponovljenih doza od 75 mg klopidogrela dnevno, inhibicija ADP-om inducirane agregacije trombocita bila je niža (25%) u ispitanika s teško narušenom funkcijom bubrega (klirens kreatinina od 5 do 15 ml/min), u usporedbi sa zdravim ispitanicima, iako je produljenje vremena krvarenja bilo slično onom zabilježenom u zdravih bolesnika koji su primali 75 mg klopidogrela dnevno.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER 4x1, 10x1, 30x1 or 100x1 tablets 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP BLISTER 4x1, 10x1, 30x1 ili 100x1 tableta
If Plavix is supplied in PVC/PVDC/aluminium blisters, store below 30°C. 
Ako je Plavix opremljen u PVC/PVDC/aluminij blistere, čuvati na temperaturi ispod 30°C.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions. 
Međutim, bolesnici koji su sudjelovali u kliničkim ispitivanjima s klopidogrelom istodobno su primali niz lijekova, među kojima su bili diuretici, beta blokatori, ACE inhibitori, antagonisti kalcija, lijekovi za snižavanje kolesterola, koronarni vazodilatatori, antidijabetici (uključujući inzulin), antiepileptici te antagonisti glikoproteina IIb/IIIa, bez znakova klinički značajnih štetnih interakcija.
Plavix is supplied in cardboard cartons containing 4x1, 10x1, 30x1 and 100x1 tablets in all aluminium perforated unit-dose blisters. 
Plavix je dostupan u kartonskim kutijama koje sadrže: 4x1, 10x1, 30x1 ili 100x1 tableta u perforiranim aluminijskim blisterima s jediničnim dozama.
Plavix is unlikely to affect your ability to drive or to use machines. 
Upravljanje vozilima i strojevima Plavix ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
In PVC/PVDC/aluminium blisters, store below 30°C. 
U PVC/PVDC/aluminij blisterima, čuvati na temperaturi ispod 30°C.
- ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300-mg loading dose in combination with ASA and with or without thrombolytics. 
- Akutni infarkt miokarda s elevacijom ST-segmenta: liječenje klopidogrelom provodi se jednom dnevnom dozom od 75 mg, a započinje udarnom dozom od 300 mg u kombinaciji s ASK te sa ili bez trombolitika.
Tablet core: mannitol (E421), hydrogenated castor oil, microcrystalline cellulose, macrogol 6000 and low-substituted hydroxypropylcellulose, Tablet coating: lactose monohydrate (milk sugar), hypromellose (E464), triacetin (E1518), red iron oxide (E172) and titanium dioxide (E171), Polishing agent: carnauba wax. 
Jezgra tablete: manitol (E421), hidrogenirano ricinusovo ulje, mikrokristalična celuloza, makrogol 6000 i nisko supstituirana hidroksipropilceluloza, Ovojnica tablete: laktoza hidrat (mliječni šećer), hipromeloza (E464), triacetin (E1518), crveni željezov oksid (E172) i titanijev dioksid (E171), Sredstvo za poliranje: karnauba vosak.
PHARMACEUTICAL PARTICULARS 6.1 List of excipients 
FARMACEUTSKI PODACI 6.1 Popis pomoćnih tvari Jezgra:
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = -4.0%; CI: -22.5 to 11.7 [p=0.639]). 
U bolesnika koji su u studiju uključeni samo zbog nedavnog infarkta miokarda, klopidogrel je bio brojčano slabiji, ali se statistički nije razlikovao od ASK (RRR = -4,0%; CI: -22,5 do 11,7 [p=0,639]).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]). 
U analizi podskupina sačinjenih prema stanju (infarkt miokarda, ishemijski moždani udar, BPA) najveću su korist od liječenja (postignuta statistička značajnost pri p = 0,003) imali bolesnici s bolešću perifernih arterija (BPA), posebno oni koji su u anamnezi imali infarkt miokarda (RRR = 23,7%; CI: 8,9 do 36,2), a manja korist (ne značajno različita od učinka ASK) uočena je u bolesnika s moždanim udarom (RRR = 7,3%; CI: -5,7 do 18,7 [p=0,258]).
Therefore clopidogrel should be used with caution in these patients (see section 4.2). 
Stoga se tim bolesnicima klopidogrel mora davati s oprezom (vidjeti dio 4.2.).
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus 
bulozni dermatitis (toksična epidermalna nekroliza, Stevens Johnsonov sindrom, erythema multiforme, akutna generalizirana egzantematozna pustuloza (AGEP)), angioedem, sindrom preosjetljivosti izazvane lijekom, osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (engl.
As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2). 
Kao mjera opreza, ne preporučuje se istodobna primjena lijekova koji su jaki ili umjereni inhibitori CYP2C19 (za popis inhibitora CYP2C19 vidjeti dio 4.5., također vidjeti dio 5.2.).
1, rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc cedex, France 
1, rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc cedex, Francuska
Plavix 75 mg film-coated tablets Clopidogrel should be given as a single daily dose of 75 mg. 
Plavix 75 mg filmom obložene tablete Klopidogrel se daje u jednokratnoj dnevnoj dozi od 75 mg.
1, rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc cedex, France or 
1, rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc cedex, Francuska ili
Therefore, concomitant use should be undertaken with caution (see section 4.4). 
Zbog toga, kod istodobne uporabe potreban je oprez (vidjeti dio 4.4.).
Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste or loss of taste of food. 
Vrlo rijetke nuspojave (mogu se javiti u manje od 1 na 10000 osoba): žutica; jaka bol u trbuhu s ili bez bolova u leđima; vrućica, teškoće pri disanju, ponekad povezane s kašljem; generalizirane alergijske reakcije (primjerice, sveukupni osjećaj vrućine s iznenadnom općom nelagodom do nesvjestice); oticanje u ustima; mjehurići na koži; kožne alergijske reakcije; upala u usnoj šupljini (stomatitis); pad krvnoga tlaka; zbunjenost; halucinacije; bol u zglobovima; bol u mišićima; poremećaj okusa ili gubitak osjeta okusa hrane.
Plavix contains lactose. 
Plavix sadrži laktozu.
Plavix 300 mg film-coated tablets This 300 mg tablet of clopidogrel is intended for use as a loading dose. 
Ova tableta od 300 mg klopidogrela namijenjena je za uporabu kao udarna doza.
Patients were randomized to receive either prasugrel 5 or 10 mg/d (Days 0-14) (n=1306), or prasugrel 5 or 10 mg/d (Days 0-7) then de-escalated to clopidogrel 75 mg/d (Days 8-14) (n=1304), in combination with ASA (<100 mg/day). 
Bolesnici su bili randomizirani tako da primaju prasugrel u dozi od 5 ili 10 mg/dan (dan 0-14) (n=1306) ili prasugrel u dozi od 5 ili 10 mg/dan (dan 0-7) nakon čega su prebačeni na de-eskaliranu terapiju - klopidogrel u dozi od 75 mg/dan (dan 8-14) (n=1304) u kombinaciji s acetilsalicilatnom kiselinom (< 100 mg/dan).
The primary outcome, a composite of cardiovascular death, stroke, urgent revascularization, and 
Primarni ishod, koji se sastojao od kardiovaskularne smrti, moždanog udara, hitne revaskularizacije i BARC (od engl.
<DD month YYYY> 
DATUM REVIZIJE TEKSTA <DD mjesec GGGG>
Plavix 75 mg film-coated tablets Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate). 
Plavix 75 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata).
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Plavix. 
Ako se bilo što od navedenog odnosi na Vas, ili niste sigurni, obratite se svom liječniku prije uzimanja Plavixa.
EU/1/98/069/001 28 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/069/002 50x1 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/069/003 84 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/069/004 100 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/069/005 30 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/069/006 90 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/069/007 14 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/069/011 7 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/069/013 28 film-coated tablets in all aluminium blisters EU/1/98/069/014 50x1 film-coated tablets in all aluminium blisters EU/1/98/069/015 84 film-coated tablets in all aluminium blisters EU/1/98/069/016 100 film-coated tablets in all aluminium blisters EU/1/98/069/017 30 film-coated tablets in all aluminium blisters EU/1/98/069/018 90 film-coated tablets in all aluminium blisters EU/1/98/069/019 14 film-coated tablets in all aluminium blisters EU/1/98/069/020 7 film-coated tablets in all aluminium blisters 
EU/1/98/069/001 28 filmom obloženih tableta u PVC/PVDC/Al blisterima EU/1/98/069/002 50x1 filmom obloženih tableta u PVC/PVDC/Al blisterima EU/1/98/069/003 84 filmom obloženih tableta u PVC/PVDC/Al blisterima EU/1/98/069/004 100 filmom obloženih tableta u PVC/PVDC/Al blisterima EU/1/98/069/005 30 filmom obloženih tableta u PVC/PVDC/Al blisterima EU/1/98/069/006 90 filmom obloženih tableta u PVC/PVDC/Al blisterima EU/1/98/069/007 14 filmom obloženih tableta u PVC/PVDC/Al blisterima EU/1/98/069/011 7 filmom obloženih tableta u PVC/PVDC/Al blisterima EU/1/98/069/013 28 filmom obloženih tableta u aluminijskim blisterima EU/1/98/069/014 50x1 filmom obloženih tableta u aluminijskim blisterima EU/1/98/069/015 84 filmom obloženih tableta u aluminijskim blisterima EU/1/98/069/016 100 filmom obloženih tableta u aluminijskim blisterima EU/1/98/069/017 30 filmom obloženih tableta u aluminijskim blisterima EU/1/98/069/018 90 filmom obloženih tableta u aluminijskim blisterima EU/1/98/069/019 14 filmom obloženih tableta u aluminijskim blisterima EU/1/98/069/020 7 filmom obloženih tableta u aluminijskim blisterima
Plavix contains lactose 
Plavix sadrži laktozu
Plavix 75 mg film-coated tablets Pink, round, biconvex, engraved with «75» on one side and «1171» on the other side. 
Plavix 75 mg filmom obložene tablete Ružičasta, okrugla, bikonveksna tableta, s urezanim brojem "75" na jednoj i "1171" na drugoj strani.